title: Evaluation of direct effects of enoximone on systemic and pulmonary vascular bed in animals with a Jarvik total artificial heart.
abstract: Enoximone, a phosphodiesterase inhibitor, has positive inotropic and vasodilating actions. To evaluate specific effects of this drug on the systemic and pulmonary vascular bed, we administered enoximone as a 10-minute intravenous bolus at two different doses of 2 and 3 mg/kg of body weight, at different days, to five Holstein calves with a Jarvik 7-70 ml total artificial heart (Symbion, Inc., Salt Lake City, Utah). The calves were monitored for aortic pressure, right atrial pressure, pulmonary arterial pressure, and left atrial pressure. For each experiment cardiac output was maintained constant, and systemic and pulmonary vascular resistances were calculated at 0, 15, 30, and 60 minutes and every hour for 8 hours after infusion. Statistical analysis used analysis of variance and the paired t test with Bonferroni's correction. Data showed the following: (1) a marked systemic vasodilating action of enoximone at peak effect at 30 minutes with a 20% decrease in systemic vascular resistance from baseline value under constant cardiac output, returning progressively to normal values throughout the 8 hours; (2) a comparable effect for the two separate doses tested; (3) no specific action on the pulmonary vascular bed with "nonunidirectional" changes in pulmonary vascular resistance. This model was validated by the infusion of prostaglandin I2 in the same animals, at different days, which significantly decreased pulmonary vascular resistance of 50% at peak effect, under constant cardiac output. In summary, enoximone showed a proper systemic vasodilating effect with no specific action on the pulmonary vascular bed in an animal model of the total artificial heart. Decrease in pulmonary vascular resistances obtained with enoximone in clinical practice seems more related to the inotropic properties of the drug. Enoximone should not be administered in pulmonary hypertension, as suggested before.
authors.affiliation: Centre de Recherches Chirurgicales, CNRS UA 1431, C.H.U. Henri Mondor, Université Paris XII, Creteil, France.
authors.forename: P H
authors.initials: PH
authors.lastname: Deleuze
authors.forename: J L
authors.initials: JL
authors.lastname: Rande
authors.forename: J
authors.initials: J
authors.lastname: Okude
authors.forename: F
authors.initials: F
authors.lastname: Wan
authors.forename: S
authors.initials: S
authors.lastname: Brunet
authors.forename: F R
authors.initials: FR
authors.lastname: Thoraval
authors.forename: J P
authors.initials: JP
authors.lastname: Cachera
authors.forename: D Y
authors.initials: DY
authors.lastname: Loisance
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002316:Cardiotonic Agents / Q000494:pharmacology*; D002417:Cattle; D017335:Enoximone; D011464:Epoprostenol / Q000494:pharmacology; D006354:Heart, Artificial; D007093:Imidazoles / Q000494:pharmacology*; D008168:Lung / Q000098:blood supply*; D008954:Models, Biological; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011474:Prosthesis Design; D014655:Vascular Resistance / Q000187:drug effects*; D014664:Vasodilation / Q000187:drug effects*
chemical_list: D002316:Cardiotonic Agents; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D017335:Enoximone; D011464:Epoprostenol